Biodefense Market By Product - Global Industry Analysis and Forecast to 2022

2018-05-30 / 3800.00 / Pharma & Healthcare / 80 Pages

Description

Industry Trend Analysis

In 2012, the global biodefense market was evaluated around USD 7.98 billion and is expected to reach approximately USD 16.16 billion by 2022 while registering itself at a compound annual growth rate (CAGR) of 7.32% over the forecast period owing to technological developments in pathogen detection method in the forensic department. A few of the modern technologies employed in biodefense are nanotechnology, database management systems, advanced detector hardware, and gene chips. The rising vaccines production, quick diagnostic procedures, superior detection and forensic therapies, and prophylactics are amongst the crucial factors anticipated to reinforce the biodefense capabilities around the globe over the projected period. Escalating investment by the local government in developed economies, like the Europe and the United States, for biodefense awareness, is expected to boost the growth during the forecast years. According to the report issued by the Centre for Research on Innovation and Science Policy, it was affirmed that the number of grants owed by the National Institutes of Health (NIH) for the progress of bioweapon agents, like anthrax, plague, glanders, brucellosis, and tularemia, had augmented by 15 times over the years, 1996-2001. Due to the augment in the number of co-owned and foreign-owned patents, a number of international associations, subcontracting, and technological collaboration agreements are increasing, which are hence anticipated to drive the market demand in the approaching few years. Furthermore, rising government intervention concerning advancing different initiatives, like the BioShield initiative was undertaken during 2004, and producing payments for private biotech firms to manufacture and develop new vaccines alongside CDC-defined category A bioterrorism threats, like tularemia, botulism, and viral hemorrhagic fevers such as Ebola. The ensuing market opportunity has contributed to collaborations among the private players as well as with several international biotechnology firms in regions, like Japan, France, Denmark, Belgium, Austria, the UK, and the Netherlands, to expand countermeasures beside biological threat agents.




Product Outlook and Trend Analysis

In 2015, Anthrax was the leading application section and reported for a market share of around 31.3%.The rising interest, as well as attempts of private players in escalating the product range providing to anthrax prevention, is expected to drive the industry growth in the approaching years. Rising government investments in the United States to produce and stockpile adequate vaccines against anthrax during various programs, like Biomedical Advanced Research and Development Authority (BARDA), BioShield Legislation, and Joint Program Executive Office for Biological and Chemical Defense, is initiating commercial opportunities for this field. The other products section reported for approximately 15% of the overall market during 2015 and is anticipated to grow at a compound annual growth rate of around 8.3% during forecast period. The viral hemorrhagic section is recognized as the most productive sector. Rapid ascend in R&D funding after the Ebola outbreaks over 2014-2015 and rising awareness concerning the prospective of the virus being utilized as a bio-weapon assigns to the abovementioned conclusion. The radiation section is also anticipated to experience rapid expansion over the forecast years. The global market is propelled by expansion in the research and development initiatives subsequent to the nuclear crisis in Japan.

Regional Outlook and Trend Analysis

In 2015, North American market appeared as the major segment reporting for over half of the global industry. Government initiatives concerning to the funding for genetic defense mechanism is a key factor pushing the expansion of the market. Though, fluctuations in financial support owing to altering government regulations might hamper demand over the forecast years. Asia Pacific region is anticipated to experience a major demand owing to rising investments in the R&D segment. Japan and Australia are a couple of the most developed Asia Pacific regional markets. The widespread vaccine production facilities offer across Japan along with the existence of advanced healthcare infrastructure in the nation is leading to its robust industry position.

Competitive Outlook and Trend Analysis

Global biodefense market is comparatively less competitive owing to dedicated nature of the products, and small commercial products demand. The major industry players are Xoma Corporation, PharmAthene, Inc., Emergent BioSolutions, Inc., Dynavax Technologies Corporation, SIGA Technologies, Inc., Elusys Therapeutics, Inc., Ichor Medical Systems, Inc., DynPort Vaccine Company, LLC, Cleveland BioLabs, Inc., Bavarian Nordic, Achaogen, Inc., Nanotherapeutics, Inc., and Alnylam Pharmaceuticals, Inc.

The global biodefense market is segmented as follows –

By Product


Anthrax
Smallpox
Botulism
Radiation/ nuclear defense
Others


By Region


North America



U.S
Canada
Mexico



Europe



Germany
France
UK
Italy
Spain
Rest of Europe



Asia-Pacific



Japan
China
Australia
India
South Korea
Rest of Asia Pacific



Rest of the World



Brazil
South Africa
Saudi Arabia
United Arab Emirates
Others


Some of the key questions answered by the report are:

· What was the market size in 2012 and forecast from 2013 to 2022`

· What will be the industry market growth from 2013 to 2022`

· What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast`

· What are the major segments leading the market growth and why`

· Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition`

Table of Content

Table of Contents
1. Introduction
1.1. Report Description
1.2. Research Methodology
1.2.1. Secondary Research
1.2.2. Primary Research
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.1.1. Presence of Favorable Government Initiatives
3.2.1.2. Emergency Use Authorization of Medical Products
3.2.2. Restraints
3.2.2.1. Low Penetration in Developing and Underdeveloped Countries
3.2.3. Opportunities
3.2.3.1. Emerging Markets to Offer Lucrative Growth Opportunities
4. Biodefense Market by Product
4.1. Introduction
4.2. Biodefense Market Assessment and Forecast, by Product, 2012-2022
4.3. Anthrax
4.3.1. Market Assessment and Forecast, by Region, 2012-2022 ($Million)
4.4. Smallpox
4.4.1. Market Assessment and Forecast, by Region, 2012-2022 ($Million)
4.5. Botulism
4.5.1. Market Assessment and Forecast, by Region, 2012-2022 ($Million)
4.6. Radiation/Nuclear
4.6.1. Market Assessment and Forecast, by Region, 2012-2022 ($Million)
4.7. Other Products
4.7.1. Market Assessment and Forecast, by Region, 2012-2022 ($Million)
4. Biodefense Market by Region
4.4. Introduction
4.5. Biodefense Market Assessment and Forecast, by Region, 2012-2022 ($Million)
4.6. North America
4.6.6. Market Assessment and Forecast, by Country, 2012-2022 ($Million)
4.6.7. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.6.8. U.S.
4.6.8.1. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.6.9. Canada
4.6.9.1. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.6.10. Mexico
4.6.10.1. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.7. Europe
4.7.6. Market Assessment and Forecast, by Country, 2012-2022 ($Million)
4.7.7. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.7.8. Germany
4.7.8.1. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.7.9. France
4.7.9.1. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.7.10. UK
4.7.10.1. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.7.11. Italy
4.7.11.1. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.7.12. Spain
4.7.12.1. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.7.13. Rest of Europe
4.7.13.1. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.8. Asia-Pacific
4.8.6. Market Assessment and Forecast, by Country, 2012-2022 ($Million)
4.8.7. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.8.8. Japan
4.8.8.1. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.8.9. China
4.8.9.1. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.8.10. Australia
4.8.10.1. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.8.11. India
4.8.11.1. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.8.12. South Korea
4.8.12.1. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.8.13. Rest of Asia-Pacific
4.8.13.1. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.9. Rest of the World
4.9.6. Market Assessment and Forecast, by Country, 2012-2022 ($Million)
4.9.7. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.9.8. Brazil
4.9.8.1. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.9.9. Turkey
4.9.9.1. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.9.10. Saudi Arabia
4.9.10.1. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.9.11. South Africa
4.9.11.1. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.9.12. United Arab Emirates
4.9.12.1. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.9.13. Others
4.9.13.1. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
5. Company Profiles
6.1. Xoma Corporation
6.1.1. Business Overview
6.1.2. Product Portfolio
6.1.3. Key Financials
6.1.4. Strategic Developments
6.2. PharmaAthene
6.2.1. Business Overview
6.2.2. Product Portfolio
6.2.3. Key Financials
6.2.4. Strategic Developments
6.3. Emergent Biosolutions
6.3.1. Business Overview
6.3.2. Product Portfolio
6.3.3. Key Financials
6.3.4. Strategic Developments
6.4. Dynavax Technologies, Inc.
6.4.1. Business Overview
6.4.2. Product Portfolio
6.4.3. Key Financials
6.4.4. Strategic Developments
6.5. SIGA Technologies
6.5.1. Business Overview
6.5.2. Product Portfolio
6.5.3. Strategic Developments
6.6. Elusys Therapeutics
6.6.1. Business Overview
6.6.2. Product Portfolio
6.6.3. Strategic Developments
6.7. Ichor Medical Systems, Inc.
6.7.1. Business Overview
6.7.2. Product Portfolio
6.7.3. Strategic Developments
6.8. DynPort Vaccine Company LLC
6.8.1. Business Overview
6.8.2. Product Portfolio
6.8.3. Strategic Developments
6.9. Cleveland BioLabs, Inc.
6.9.1. Business Overview
6.9.2. Product Portfolio
6.9.3. Strategic Developments
6.10. Bavarian Nordic
6.10.1. Business Overview
6.10.2. Product Portfolio
6.10.3. Strategic Developments
6.11. Achaogen
6.11.1. Business Overview
6.11.2. Product Portfolio
6.11.3. Key Financials
6.11.4. Strategic Developments


Table of Figures

List of Tables
Table 1.Biodefense Market by Product ($Million), 2012-2022
Table 2.Anthrax Market, by Type ($Million), 2012-2022
Table 3.Smallpox Market, by Region ($Million), 2012-2022
Table 4.Botulism Market, by Region ($Million), 2012-2022
Table 5.Radiation/ nuclear defense Market, by Region ($Million), 2012-2022
Table 6.Other Products Market, by Region ($Million), 2012-2022
Table 7.North America Biodefense Market by Country, 2012-2022 ($Million)
Table 8.North America Biodefense Market, by Product2012-2022 ($Million)
Table 9.U.S.Biodefense Market, by Product2012-2022 ($Million)
Table 10.Canada Biodefense Market, by Product2012-2022 ($Million)
Table 11.Mexico Biodefense Market, by Product2012-2022 ($Million)
Table 12.Europe Biodefense Market by Country, 2012-2022 ($Million)
Table 13.Europe Biodefense Market, by Product2012-2022 ($Million)
Table 14.Germany Biodefense Market, by Product2012-2022 ($Million)
Table 15.France Biodefense Market, by Product2012-2022 ($Million)
Table 16.UK Biodefense Market, by Product2012-2022 ($Million)
Table 17.Italy Biodefense Market, by Product2012-2022 ($Million)
Table 18.Spain Biodefense Market, by Product2012-2022 ($Million)
Table 19.Rest of Europe Biodefense Market, by Product2012-2022 ($Million)
Table 20.Asia-Pacific Biodefense Market by Country, 2012-2022 ($Million)
Table 21.Asia-Pacific Biodefense Market, by Product2012-2022 ($Million)
Table 22.Japan Biodefense Market, by Product2012-2022 ($Million)
Table 23.China Biodefense Market, by Product2012-2022 ($Million)
Table 24.Australia Biodefense Market, by Product2012-2022 ($Million)
Table 25.India Biodefense Market, by Product2012-2022 ($Million)
Table 26.South Korea Biodefense Market, by Product2012-2022 ($Million)
Table 27.Rest of Asia-Pacific Biodefense Market, by Product2012-2022 ($Million)
Table 28.Rest of the World Biodefense Market by Country, 2012-2022 ($Million)
Table 29.Rest of the World Biodefense Market, by Product2012-2022 ($Million)
Table 30.Brazil Biodefense Market, by Product2012-2022 ($Million)
Table 31.Turkey Biodefense Market, by Product2012-2022 ($Million)
Table 32.Saudi Arabia Biodefense Market, by Product2012-2022 ($Million)
Table 33.South Africa Biodefense Market, by Product2012-2022 ($Million)
Table 34.United Arab Emirates Biodefense Market, by Product2012-2022 ($Million)
Table 35.Others Biodefense Market, by Product2012-2022 ($Million)
Table 36.Tosoh Corporation: Key Strategic Developments, 2015-2017
Table 37.Arkema Group: Key Strategic Developments, 2015-2017
Table 38.BASF SE: Key Strategic Developments, 2015-2017
Table 39.Interra Global Corporation: Key Strategic Developments, 2015-2017
Table 40.UOP LLC: Key Strategic Developments, 2015-2017
Table 41.Zeochem AG: Key Strategic Developments, 2015-2017
Table 42.Grace Catalysts Technologies: Key Strategic Developments, 2015-2017
Table 43.Chemiewerk Bad Köstritz: Key Strategic Developments, 2015-2017
Table 44.Tricat Group: Key Strategic Developments, 2015-2017
Table 45.KNT Group: Key Strategic Developments, 2015-2017
Table 46.Zeox Corporation: Key Strategic Developments, 2015-2017

Request Sample

* mark fields are compulsory